Brazil signs technology transfer deals worth $1.5 billion
This article was originally published in Scrip
Pfizer, the Israeli firm Protalix and the Brazilian health ministry have signed a R$1.25 billion ($734 million) technology transfer deal that will see the state-owned pharmaceutical lab, Biomanguinhos, produce generic versions of Uplyso (taliglucerase alfa) for Gaucher's disease within five years.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.